Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis
IntroductionBaricitinib is a selective inhibitor of Janus kinase (JAK)1 and JAK2, which is associated with clinical improvement in non-severe COVID-19 patients. But in severe COVID-19 patients, the effectiveness of baricitinib is still controversial.MethodsA propensity score-matched and retrospectiv...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1445809/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591945173565440 |
|---|---|
| author | Yanxiong Mao Anyi Guo Ying Zhang Jianxing Lai Dian Yuan Hao Zhang Wenqi Diao Weisong Chen Fugui Yan |
| author_facet | Yanxiong Mao Anyi Guo Ying Zhang Jianxing Lai Dian Yuan Hao Zhang Wenqi Diao Weisong Chen Fugui Yan |
| author_sort | Yanxiong Mao |
| collection | DOAJ |
| description | IntroductionBaricitinib is a selective inhibitor of Janus kinase (JAK)1 and JAK2, which is associated with clinical improvement in non-severe COVID-19 patients. But in severe COVID-19 patients, the effectiveness of baricitinib is still controversial.MethodsA propensity score-matched and retrospective study was conducted to evaluate the effectiveness of baricitinib in severe COVID-19 patients requiring invasive mechanical ventilation (IMV).ResultsA total number of 48 patients treated with baricitinib were included, and 48 patients were assigned to control group by propensity score matching. The mean ages were high in both group (baricitinib group vs. control group: 78.80 ± 9.04 vs. 82.57 ± 9.27), and most were unvaccinated (62.5% vs. 66.7%. Baricitinib group had a higher proportion of patients with hypertension (73.9% vs. 45.5%, p = 0.006). Control group had higher level of creatine kinase-myocardial band (247.50 vs. 104.50, p = 0.021). Patients in the baricitinib group were more likely to receive nirmatrelvir/ritonavir (39.6% vs. 16.7%, p = 0.017) and intravenous immunoglobin (14.6% vs. 0, p = 0.007). Baricitinib group had significantly lower all-cause 28-days mortality than control group (72.9% vs. 89.6%, p = 0.004).ConclusionThe present study revealed baricitinib reduced 28-days mortality in severe COVID-19 patients on IMV. The effectiveness of baricitinib in treating patients with severe COVID-19 on IMV needs to be further investigated through future studies. |
| format | Article |
| id | doaj-art-f0d7b8ac0f574b1aa5b1d48c9a39217e |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-f0d7b8ac0f574b1aa5b1d48c9a39217e2025-01-22T05:19:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011210.3389/fmed.2025.14458091445809Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysisYanxiong Mao0Anyi Guo1Ying Zhang2Jianxing Lai3Dian Yuan4Hao Zhang5Wenqi Diao6Weisong Chen7Fugui Yan8Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Scientific Research, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Respiratory, Jinhua Municipal Central Hospital, Jinhua, Zhejiang, ChinaKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaIntroductionBaricitinib is a selective inhibitor of Janus kinase (JAK)1 and JAK2, which is associated with clinical improvement in non-severe COVID-19 patients. But in severe COVID-19 patients, the effectiveness of baricitinib is still controversial.MethodsA propensity score-matched and retrospective study was conducted to evaluate the effectiveness of baricitinib in severe COVID-19 patients requiring invasive mechanical ventilation (IMV).ResultsA total number of 48 patients treated with baricitinib were included, and 48 patients were assigned to control group by propensity score matching. The mean ages were high in both group (baricitinib group vs. control group: 78.80 ± 9.04 vs. 82.57 ± 9.27), and most were unvaccinated (62.5% vs. 66.7%. Baricitinib group had a higher proportion of patients with hypertension (73.9% vs. 45.5%, p = 0.006). Control group had higher level of creatine kinase-myocardial band (247.50 vs. 104.50, p = 0.021). Patients in the baricitinib group were more likely to receive nirmatrelvir/ritonavir (39.6% vs. 16.7%, p = 0.017) and intravenous immunoglobin (14.6% vs. 0, p = 0.007). Baricitinib group had significantly lower all-cause 28-days mortality than control group (72.9% vs. 89.6%, p = 0.004).ConclusionThe present study revealed baricitinib reduced 28-days mortality in severe COVID-19 patients on IMV. The effectiveness of baricitinib in treating patients with severe COVID-19 on IMV needs to be further investigated through future studies.https://www.frontiersin.org/articles/10.3389/fmed.2025.1445809/fullCOVID-19baricitinibmortalitypropensity score matchinginvasive mechanical ventilation |
| spellingShingle | Yanxiong Mao Anyi Guo Ying Zhang Jianxing Lai Dian Yuan Hao Zhang Wenqi Diao Weisong Chen Fugui Yan Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis Frontiers in Medicine COVID-19 baricitinib mortality propensity score matching invasive mechanical ventilation |
| title | Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis |
| title_full | Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis |
| title_fullStr | Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis |
| title_full_unstemmed | Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis |
| title_short | Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis |
| title_sort | baricitinib treatment for hospitalized patients with severe covid 19 on invasive mechanical ventilation a propensity score matched and retrospective analysis |
| topic | COVID-19 baricitinib mortality propensity score matching invasive mechanical ventilation |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1445809/full |
| work_keys_str_mv | AT yanxiongmao baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis AT anyiguo baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis AT yingzhang baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis AT jianxinglai baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis AT dianyuan baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis AT haozhang baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis AT wenqidiao baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis AT weisongchen baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis AT fuguiyan baricitinibtreatmentforhospitalizedpatientswithseverecovid19oninvasivemechanicalventilationapropensityscorematchedandretrospectiveanalysis |